Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Dermatomyositis Drug Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Dermatomyositis Drug Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Abatacept
      • 1.3.3 Baricitinib
      • 1.3.4 Dalazatide
      • 1.3.5 Immune Globulin
      • 1.3.6 IMO-8400
      • 1.3.7 Others
    • 1.4 Market Segment by Application
      • 1.4.1 Global Dermatomyositis Drug Market Share by Application (2019-2025)
      • 1.4.2 Hospital
      • 1.4.3 Clinic
      • 1.4.4 Others
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Dermatomyositis Drug Market Size
      • 2.1.1 Global Dermatomyositis Drug Revenue 2014-2025
      • 2.1.2 Global Dermatomyositis Drug Sales 2014-2025
    • 2.2 Dermatomyositis Drug Growth Rate by Regions
      • 2.2.1 Global Dermatomyositis Drug Sales by Regions 2014-2019
      • 2.2.2 Global Dermatomyositis Drug Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Dermatomyositis Drug Sales by Manufacturers
      • 3.1.1 Dermatomyositis Drug Sales by Manufacturers 2014-2019
      • 3.1.2 Dermatomyositis Drug Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Dermatomyositis Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Dermatomyositis Drug Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Dermatomyositis Drug Market Concentration Ratio (CR5 and HHI)
    • 3.3 Dermatomyositis Drug Price by Manufacturers
    • 3.4 Key Manufacturers Dermatomyositis Drug Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Dermatomyositis Drug Market
    • 3.6 Key Manufacturers Dermatomyositis Drug Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Abatacept Sales and Revenue (2014-2019)
      • 4.1.2 Baricitinib Sales and Revenue (2014-2019)
      • 4.1.3 Dalazatide Sales and Revenue (2014-2019)
      • 4.1.4 Immune Globulin Sales and Revenue (2014-2019)
      • 4.1.5 IMO-8400 Sales and Revenue (2014-2019)
      • 4.1.6 Others Sales and Revenue (2014-2019)
    • 4.2 Global Dermatomyositis Drug Sales Market Share by Type
    • 4.3 Global Dermatomyositis Drug Revenue Market Share by Type
    • 4.4 Dermatomyositis Drug Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Dermatomyositis Drug Sales by Application

    6 United States

    • 6.1 United States Dermatomyositis Drug Breakdown Data by Company
    • 6.2 United States Dermatomyositis Drug Breakdown Data by Type
    • 6.3 United States Dermatomyositis Drug Breakdown Data by Application

    7 European Union

    • 7.1 European Union Dermatomyositis Drug Breakdown Data by Company
    • 7.2 European Union Dermatomyositis Drug Breakdown Data by Type
    • 7.3 European Union Dermatomyositis Drug Breakdown Data by Application

    8 China

    • 8.1 China Dermatomyositis Drug Breakdown Data by Company
    • 8.2 China Dermatomyositis Drug Breakdown Data by Type
    • 8.3 China Dermatomyositis Drug Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Dermatomyositis Drug Breakdown Data by Company
    • 9.2 Rest of World Dermatomyositis Drug Breakdown Data by Type
    • 9.3 Rest of World Dermatomyositis Drug Breakdown Data by Application
    • 9.4 Rest of World Dermatomyositis Drug Breakdown Data by Countries
      • 9.4.1 Rest of World Dermatomyositis Drug Sales by Countries
      • 9.4.2 Rest of World Dermatomyositis Drug Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 MedImmune LLC
      • 10.1.1 MedImmune LLC Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Dermatomyositis Drug
      • 10.1.4 Dermatomyositis Drug Product Introduction
      • 10.1.5 MedImmune LLC Recent Development
    • 10.2 Neovacs SA
      • 10.2.1 Neovacs SA Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Dermatomyositis Drug
      • 10.2.4 Dermatomyositis Drug Product Introduction
      • 10.2.5 Neovacs SA Recent Development
    • 10.3 Novartis AG
      • 10.3.1 Novartis AG Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Dermatomyositis Drug
      • 10.3.4 Dermatomyositis Drug Product Introduction
      • 10.3.5 Novartis AG Recent Development
    • 10.4 Octapharma AG
      • 10.4.1 Octapharma AG Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Dermatomyositis Drug
      • 10.4.4 Dermatomyositis Drug Product Introduction
      • 10.4.5 Octapharma AG Recent Development
    • 10.5 Pfizer Inc
      • 10.5.1 Pfizer Inc Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Dermatomyositis Drug
      • 10.5.4 Dermatomyositis Drug Product Introduction
      • 10.5.5 Pfizer Inc Recent Development
    • 10.6 Eli Lilly and Company
      • 10.6.1 Eli Lilly and Company Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Dermatomyositis Drug
      • 10.6.4 Dermatomyositis Drug Product Introduction
      • 10.6.5 Eli Lilly and Company Recent Development
    • 10.7 F. Hoffmann-La Roche Ltd
      • 10.7.1 F. Hoffmann-La Roche Ltd Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Dermatomyositis Drug
      • 10.7.4 Dermatomyositis Drug Product Introduction
      • 10.7.5 F. Hoffmann-La Roche Ltd Recent Development
    • 10.8 Hope Pharmaceuticals Inc
      • 10.8.1 Hope Pharmaceuticals Inc Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Dermatomyositis Drug
      • 10.8.4 Dermatomyositis Drug Product Introduction
      • 10.8.5 Hope Pharmaceuticals Inc Recent Development
    • 10.9 Idera Pharmaceuticals Inc
      • 10.9.1 Idera Pharmaceuticals Inc Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Dermatomyositis Drug
      • 10.9.4 Dermatomyositis Drug Product Introduction
      • 10.9.5 Idera Pharmaceuticals Inc Recent Development
    • 10.10 KPI Therapeutics Inc
      • 10.10.1 KPI Therapeutics Inc Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Dermatomyositis Drug
      • 10.10.4 Dermatomyositis Drug Product Introduction
      • 10.10.5 KPI Therapeutics Inc Recent Development
    • 10.11 Marathon Pharmaceuticals LLC

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Dermatomyositis Drug Sales Channels
      • 11.2.2 Dermatomyositis Drug Distributors
    • 11.3 Dermatomyositis Drug Customers

    12 Market Forecast

    • 12.1 Global Dermatomyositis Drug Sales and Revenue Forecast 2019-2025
    • 12.2 Global Dermatomyositis Drug Sales Forecast by Type
    • 12.3 Global Dermatomyositis Drug Sales Forecast by Application
    • 12.4 Dermatomyositis Drug Forecast by Regions
      • 12.4.1 Global Dermatomyositis Drug Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Dermatomyositis Drug Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      In 2019, the market size of Dermatomyositis Drug is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Dermatomyositis Drug.

      This report studies the global market size of Dermatomyositis Drug, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Dermatomyositis Drug sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      MedImmune LLC
      Neovacs SA
      Novartis AG
      Octapharma AG
      Pfizer Inc
      Eli Lilly and Company
      F. Hoffmann-La Roche Ltd
      Hope Pharmaceuticals Inc
      Idera Pharmaceuticals Inc
      KPI Therapeutics Inc
      Marathon Pharmaceuticals LLC

      Market Segment by Product Type
      Abatacept
      Baricitinib
      Dalazatide
      Immune Globulin
      IMO-8400
      Others

      Market Segment by Application
      Hospital
      Clinic
      Others

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Dermatomyositis Drug status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Dermatomyositis Drug manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Dermatomyositis Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now